<DOC>
	<DOCNO>NCT02107898</DOCNO>
	<brief_summary>Primary Objective : To demonstrate reduction low-density lipoprotein cholesterol ( LDL-C ) alirocumab add-on therapy stable daily statin therapy without lipid modify therapy comparison placebo 24 week treatment heterozygous familial hypercholesterolemia ( HeFH ) high cardiovascular risk participant hypercholesterolemia . Secondary Objectives : - To evaluate effect alirocumab comparison placebo LDL-C 12 week treatment . - To evaluate effect alirocumab lipid parameter . - To evaluate long-term effect alirocumab comparison placebo LDL-C 52 week treatment . - To evaluate safety tolerability alirocumab . - To evaluate development anti-alirocumab antibody . - To evaluate pharmacokinetics alirocumab .</brief_summary>
	<brief_title>Efficacy Safety Evaluation Alirocumab Patients With Heterozygous Familial Hypercholesterolemia High Cardiovascular Risk Patients With Hypercholesterolemia Lipid Modifying Therapy ( ODYSSEY JAPAN )</brief_title>
	<detailed_description>Total duration per participant approximately 63 week ( 14 month ) ( screen : 3 week , double-blind treatment period : 52 week , follow-up period : 8 week ) .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Participants heterozygous familial hypercholesterolemia nonfamilial hypercholesterolemia adequately control stable daily dose statin without lipid modifying therapy , stable dose prior screen visit ( Week 3 ) . Exclusion criterion : 1 . LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) screen visit participant heterozygous familial hypercholesterolemia participant nonfamilial hypercholesterolemia history document coronary heart disease describe Japan Atherosclerosis Society ( JAS ) Guidelines Prevention Atherosclerotic Cardiovascular Diseases 2012 . 2 . LDLC &lt; 120 mg/dL ( &lt; 3.10 mmol/L ) screen visit participant nonfamilial hypercholesterolemia history document disease risk factor categorize primary prevention category III describe JAS Guidelines Prevention Atherosclerotic Cardiovascular Diseases 2012 . 3 . Not stable daily dose lipid modify therapy ( include statin ) within 4 week prior screen visit screen randomization visit . 4 . Age &lt; 20 year screen visit . The information intend contain consideration relevant participant ' potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>